POINT Biopharma Global Inc. Common Stock
PNT was delisted on the 26th of December, 2023.
55 hedge funds and large institutions have $194M invested in POINT Biopharma Global Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 19 increasing their positions, 6 reducing their positions, and 4 closing their positions.
525% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 4
217% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 6
62% more funds holding
Funds holding: 34 → 55 (+21)
22% less capital invested
Capital invested by funds: $248M → $194M (-$53.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.83M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$3.36M |
| 3 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$3.15M |
| 4 |
SCM
Sio Capital Management
New York
|
+$2.83M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$4.38M |
| 2 |
BCP
Berylson Capital Partners
Boston,
Massachusetts
|
-$2.97M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$1.7M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.1M |
| 5 |
PA
Perceptive Advisors
New York
|
-$367K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Osaic Holdings
Scottsdale,
Arizona
| $15K | +$20K | +2,670 | New |
|
52
UBS Group
Zurich,
Switzerland
| $14K | +$18.4K | +2,455 | New |
|
53
Ensign Peak Advisors
Salt Lake City,
Utah
| $7K | +$9.98K | +1,330 | New |
|
54
Citigroup
New York
| $4K | +$4.98K | +664 | New |
|
55
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $2K | +$1.5K | +200 | New |
|
|
BCP
56
Berylson Capital Partners
Boston,
Massachusetts
| – | -$2.97M | -386,221 | Closed |
|
|
CPIG
57
Chicago Partners Investment Group
Chicago,
Illinois
| – | -$92K | -10,295 | Closed |
|
|
PHK
58
Point72 Hong Kong
Hong Kong
| – | -$63K | -8,241 | Closed |
|
|
CSS
59
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$28K | -3,637 | Closed |
|
PNT Hedge Fund Activity: Q4 2021 in Review
55 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q4 2021, worth a combined $194M — down 22% from $248M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new PNT positions and 4 closed out — a net gain of 21 holders — while 19 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $6.83M. The largest seller was Farallon Capital Management, cutting an estimated $4.38M.
- 55 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q4 2021, up from 34 in Q3 2021.
- Funds reported $194M of POINT Biopharma Global Inc. Common Stock stock for Q4 2021, down 22% quarter-over-quarter.
- 25 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q4 2021 and 4 closed out, a net change of +21 holders.
- The largest POINT Biopharma Global Inc. Common Stock buyer in Q4 2021 was BlackRock, an estimated $6.83M added.
- The largest POINT Biopharma Global Inc. Common Stock seller in Q4 2021 was Farallon Capital Management, an estimated $4.38M sold.
Based on aggregated 13F filings for Q4 2021.